These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35624992)

  • 1. Post-Stroke Asymmetric Prurigo Nodularis Responding to Dupilumab Treatment: A Case Report.
    Sammarra I; Bennardo L; Provenzano E; Patruno C; Nisticò SP
    Brain Sci; 2022 May; 12(5):. PubMed ID: 35624992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A critical review of dupilumab for adult patients with prurigo nodularis.
    Biazus Soares G; Yosipovitch G
    Expert Rev Clin Immunol; 2024 Mar; 20(3):249-254. PubMed ID: 37811660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupilumab for the Treatment of Prurigo Nodularis.
    Alkhaleefa A; Woo TE; Parsons L
    Skin Therapy Lett; 2023 Nov; 28(6):7-9. PubMed ID: 38016088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
    Husein-ElAhmed H; Steinhoff M
    J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prurigo nodularis: new insights into pathogenesis and novel therapeutics.
    Liao V; Cornman HL; Ma E; Kwatra SG
    Br J Dermatol; 2024 May; 190(6):798-810. PubMed ID: 38345154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of dupilumab in prurigo nodularis in elderly patient.
    Giura MT; Viola R; Fierro MT; Ribero S; Ortoncelli M
    Dermatol Ther; 2020 Jan; 33(1):e13201. PubMed ID: 31856368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study.
    Fang HY; Lian CH
    J Dermatol; 2023 Aug; 50(8):1084-1087. PubMed ID: 37088954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A real-world observational study of dupilumab treatment in adult patients with prurigo nodularis.
    Zhang Z; Li S; Wang Y; Zhao J
    An Bras Dermatol; 2023; 98(4):440-448. PubMed ID: 36966024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A critical evaluation of nemolizumab for prurigo nodularis.
    Brooks SG; Yosipovitch G
    Expert Rev Clin Immunol; 2024 Jun; 20(6):577-587. PubMed ID: 38217530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab as promising treatment for prurigo nodularis: current evidences.
    Toffoli L; Farinazzo E; Zelin E; Agozzino M; Dianzani C; Di Meo N; Nan K; Zalaudek I; Conforti C
    J Dermatolog Treat; 2022 May; 33(3):1306-1311. PubMed ID: 33588666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recalcitrant prurigo nodularis treated successfully with dupilumab.
    Rambhia PH; Levitt JO
    JAAD Case Rep; 2019 May; 5(5):471-473. PubMed ID: 31192991
    [No Abstract]   [Full Text] [Related]  

  • 12. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.
    Yosipovitch G; Mollanazar N; Ständer S; Kwatra SG; Kim BS; Laws E; Mannent LP; Amin N; Akinlade B; Staudinger HW; Patel N; Yancopoulos GD; Weinreich DM; Wang S; Shi G; Bansal A; O'Malley JT
    Nat Med; 2023 May; 29(5):1180-1190. PubMed ID: 37142763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prurigo Nodularis: Review and Emerging Treatments.
    Leis M; Fleming P; Lynde CW
    Skin Therapy Lett; 2021 May; 26(3):5-8. PubMed ID: 34077168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of biologics in prurigo nodularis.
    Müller S; Bieber T; Ständer S
    Expert Opin Biol Ther; 2022 Jan; 22(1):47-58. PubMed ID: 34289753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. INDIVIDUAL ARTICLE: Management of Prurigo Nodularis.
    Elmariah SB; Tao L; Valdes-Rodriguez R; Laquer V
    J Drugs Dermatol; 2023 Dec; 22(12):SF365502s15-SF365502s22. PubMed ID: 38051855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab for prurigo nodularis: Case series and review of the literature.
    Holm JG; Agner T; Sand C; Thomsen SF
    Dermatol Ther; 2020 Mar; 33(2):e13222. PubMed ID: 31917498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks.
    Paganini C; Talamonti M; Maffei V; Di Raimondo C; Bianchi L; Galluzzo M
    J Clin Med; 2024 Feb; 13(3):. PubMed ID: 38337572
    [No Abstract]   [Full Text] [Related]  

  • 18. Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2).
    Yosipovitch G; Kim BS; Kwatra SG; Mollanazar NK; Ständer S; Satoh T; Mendes-Bastos P; Tsai TF; Laws E; Nivens MC; Maloney J; Shi G; Bansal A; Dubost-Brama A
    JAAD Int; 2024 Sep; 16():163-174. PubMed ID: 39006917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
    Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF
    EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy.
    Ferrucci S; Tavecchio S; Berti E; Angileri L
    J Dermatolog Treat; 2021 Jun; 32(4):453-454. PubMed ID: 31442084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.